Bli medlem
Bli medlem

Du är här


Medigene AG: Medigene sells partial stake in Immunocore

Medigene AG / Medigene sells partial stake in Immunocore. Processed and
transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
Martinsried/Munich, 04 April 2016
.Medigene AG(MDG1, Frankfurt, Prime Standard), a clinical stage
immune-oncology company focussing on the development of T cell-based
immunotherapies for the treatment of cancer, announces that it has today sold
50% of its' stake in the private biotech company Immunocore Ltd., UK, for
approximately 4.9 million GBP (approx. € 6.1 million).

Medigene held 64,815 ordinary shares in Immunocore which were valued at 2.8
million GBP (approx. € 3.6 million) in 2014.

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. The company is developing
highly innovative, complementary treatment platforms to target various types
and stages of cancer with candidates in clinical and pre-clinical
development. Medigene concentrates on the development of personalised
T-cell-based immunotherapies.

For more information, please

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene®is a registered trademark of Medigene
AG. This trademark may be owned or licensed in select locations only.

Contact Medigene

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01

In case you no longer wish to receive any information about Medigene, please
inform us by e-mail ( We will then delete your address
from our distribution list.

Press release English PDF


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.